中文
English
한국어
日本語
Español
Français
Русский
| カタログ番号 | HB941126 |
|---|---|
| 種反応性 | Human |
| アプリケーション | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| 宿主種 | Human |
| クローン性 | Monoclonal |
| アイソタイプ | IgG |
| クローンID | VGX200 |
| ターゲット | L-VEGF, N-VEGF, VEGF, VEGFA, VPF, Vascular endothelial growth factor A, long form, Vascular permeability factor |
| エンドトキシンレベル | < 10 EU/mg |
| 純度 | >95% as determined by SDS-PAGE. |
| 精製 | Protein A/G purified from cell culture supernatant. |
| アクセッション番号 | P15692 |
| 形態 | Liquid |
| 保存バッファー | 0.01M PBS pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
| 安定性と保存 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 別名 | VGX200 |
| 背景 | Vascular endothelial growth factor A, long form (VEGFA) is a ~43 kDa protein. Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A. Involved in protecting cells from hypoxia-mediated cell death. VEGFA is the therapeutic target of bevacizumab (Avastin). 1. Katsman, M. et al. (2022) Cells 11. PMID: 35455969 |
| 参考文献 | 1. Paul Anthony Stupple, et al. 3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies. US10519167B2. 2019-12-31. [HB941126] 2. METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECT. EP003721872B1. 2025-01-22. [HB941126] |
| 注意事項 | For research use only. Not suitable for clinical or therapeutic use. |
SDS-PAGE for Research Grade Anti-Human VEGFA (VGX200)
+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206
